- Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutationsWang, Jie; Wang, Zhijie; Wu, Lin; Li, Baolan; Cheng, Ying; Li, Xiaoling; Wang, Xicheng; Han, Liang; Wu, Xiaohong; Fan, Yun; Yu, Yan; Lv, Dongqing; Shi, Jianhua; Huang, Jianjin; Zhou, Shaozhang; Han, Baohui; Sun, Guogui; Guo, Qisen; Ji, Youxin; Zhu, XiaoliAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations.Wang, Jie; Wang, Zhijie; Wu, Lin; Li, Baolan; Cheng, Ying; Li, Xiaoling; Wang, Xicheng; Han, Liang; Wu, Xiaohong; Fan, Yun; Yu, Yan; Lv, Dongqing; Shi, Jianhua; Huang, Jianjin; Zhou, Shaozhang; Han, Baohui; Sun, Guogui; Guo, Qisen; Ji, Youxin; Zhu, XiaoliAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- Phase I/II combination study of tifcemalimab with toripalimab in patients with refractory extensive stage small cell lung cancer (ES-SCLC)Cheng, Ying; Wang, Jie; Yu, Yan; Wang, Qiming; Yang, Runxiang; Lv, Dongqing; Xia, Bing; Yi, Tienan; Li, Chong; Wang, Xicheng; Zhang, Wei; Han, Liang; Liu, Xiaoqing; Shen, Minjie; Xu, Jing; Xue, Peng; Wang, WeihuaAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker
11阅读
